First-order Wiener kernel visually evoked potentials obtained from multiple sclerosis patients

1987 ◽  
Vol 65 (1) ◽  
pp. 125-134 ◽  
Author(s):  
Doris V. Schoon ◽  
Edward K. Wong
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Visually Evoked Potentials ◽  
First Order ◽  
Wiener Kernel ◽  
Multiple Sclerosis Patients

Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy

2016 ◽  
Vol 365 ◽  
pp. 143-146 ◽  
Author(s):  
R. Iodice ◽  
A. Carotenuto ◽  
R. Dubbioso ◽  
I. Cerillo ◽  
L. Santoro ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Multimodal Evoked Potentials ◽  
Multiple Sclerosis Patients

MRI and visual-evoked potentials in partners of multiple sclerosis patients

2011 ◽  
Vol 125 (6) ◽  
pp. 424-430 ◽  
Author(s):  
C. H. Hawkes ◽  
S. Chawda ◽  
S. Derakshani ◽  
N. Muhammed ◽  
E. Visentin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Visual Evoked Potentials ◽  
Multiple Sclerosis Patients ◽  
Visual Evoked

Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis

2010 ◽  
Vol 17 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Sven G Meuth ◽  
Stefan Bittner ◽  
Carola Seiler ◽  
Kerstin Göbel ◽  
Heinz Wiendl
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Motor Evoked Potentials ◽  
Sum Score ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Sum Scores ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Background and Objective: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing–remitting multiple sclerosis patients. Methods: EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale. Results: Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment ( p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level. Conclusions: Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems.

scholarly journals Assessment of visual and auditory evoked potentials in multiple sclerosis patients with and without fatigue

2014 ◽  
Vol 36 (2) ◽  
pp. 235-242 ◽  
Author(s):  
Anna Pokryszko-Dragan ◽  
Malgorzata Bilinska ◽  
Ewa Gruszka ◽  
Elżbieta Kusinska ◽  
Ryszard Podemski
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Auditory Evoked Potentials ◽  
Multiple Sclerosis Patients
Sign in / Sign up

Export Citation Format

Share Document